Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs by Lindsey Burggraaff (6243110)

“…Endogenous ligands, such as hormones and neurotransmitters, bind to the orthosteric site, while synthetic ligands may bind to orthosteric or allosteric sites, which has become a focal point in drug discovery. Usually, such allosteric modulators bind to a protein noncompetitively with its endogenous ligand or substrate. …”

Characterization of the short- and long-term synaptic plasticity in <i>Lcn2</i>-KO mice. by Jae-Hong Kim (124622)

Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes by Shiliang Li (298790)

“…The long-term antidiabetic efficacies of <b>5</b> (10 mg/kg, qw) were better than those of the once-weekly trelagliptin and omarigliptin, especially in decreasing the hemoglobin A1c level.…”

Gene Ontology network analysis of differentially-enriched Vpu-proximal protein subsets. by Charlotte A. Stoneham (10819125)

Uncertainty analyses of unadjusted data from Scenarios 1–3: each dot represents one simulation. by Jie Lou (535356)

Pair-wise comparison of the proximity-ome of wild type Vpu relative to the transmembrane domain mutant AAA/F. by Charlotte A. Stoneham (10819125)

IC₅₀ values of REJO SP mutants vs. WT by MAbs targeting V2i, V3, V2q, and the CD4bs and by CD-IgG2. by Chitra Upadhyay (817121)

Results of parameter estimation and comparison. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

Distribution of nod lengths. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

Terminology used in this study. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

MAEs of each window size. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

Screenshot of the corpus. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

Posterior distribution of fixed effects. by Taiga Mori (21410076)

“…We then define the magnitude as the difference between the lowest and highest points of the head within a cycle. In the analysis, we demonstrate that this magnitude varies depending on length and position, thereby providing evidence that nods exhibit a structured pattern. …”

MRP1 activity in astrocytes (A) and endothelial cells HUVEC (B). by Catarina Rapôso (5660521)

“…In endothelial cells, PNV induced a decrease in fluorescence at 15 min time-point, but not at 5 h. 7NI+PNV induced more significant MRP1 activity both at 15 min and 5 h in endothelial cells. 7NI treatment <i>per se</i> (used as a control of 7NI/PNV) showed no change in the MRP1 activity relative to 7NI/PNV. …”

Juxtanuclear endosomal distortion in cells expressing Vpu-S52,56N-APEX2. by Charlotte A. Stoneham (10819125)

Vpu-APEX2 fusion protein design and activity. by Charlotte A. Stoneham (10819125)

Longitudinal associations between baseline CVR and 2 years changes in BDI-II score in participants with a BDI-II score <18 in the PREDIMED-PLUS trial at baseline. by Sandra Martín-Peláez (11353470)

Association between cardiovascular risk and a) depressive status (BDI-II ≥18) and b) BDI-II score, in the PREDIMED-PLUS trial, stratified by CVR factors, at baseline. by Sandra Martín-Peláez (11353470)

Table_5_New evidence for the effect of type 2 diabetes and glycemic traits on testosterone levels: a two-sample Mendelian randomization study.xlsx by Chengyang Jiang (1540369)

Scheme [37] and photo of a device for extracting tritium from plants’ tissue free water (1 –organic glass container; 2 –lid; 3 –cone-shaped refrigerator; 4 –receiving tank holder;... by Yelena Polivkina (14341291)